15 Most Successful Penny Stocks in History
While most of us hear the words "the broader market" or use it in conversations and investing, usually refer only to a small part of the stock market.
Pharmacyclics Inc (PCYC)
This company is not actively trading or the ticker does belong to another company in our database now.
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Two Sigma Advisors John Overdeck And David Siegel | 0 | $0 | 0% | |
| 2. | 0 | $0 | 0% | ||
| 3. | Alpine Associates Robert Emil Zoellner | 0 | $0 | 0% | |
| 4. | 0 | $0 | 0% | ||
| 5. | Andromeda Capital Larry Motola | 0 | $0 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $20.85 | 150,000 | $3,128,040.00 | 557,211 | 2012-02-10 | Filing | |
| $17.89 | 12,907 | $230,942.37 | 407,211 | 2012-01-26 | Filing | |
| $17.95 | 28,966 | $519,959.98 | 394,304 | 2012-01-26 | Filing | |
| $18.43 | 3,018 | $55,629.29 | 365,338 | 2012-01-25 | Filing | |
| $18.55 | 18,547 | $343,996.77 | 362,320 | 2012-01-25 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $254.11 | 30,000 | $7,623,444.00 | 225,312 | 2015-03-11 | Filing | |
| $254.91 | 2,514 | $640,853.80 | 54,611 | 2015-03-13 | Filing | |
| $254.88 | 902 | $229,901.76 | 57,125 | 2015-03-13 | Filing | |
| $254.15 | 24,098 | $6,124,506.70 | 58,027 | 2015-03-11 | Filing | |
| $254.11 | 30,000 | $7,623,444.00 | 225,312 | 2015-03-11 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 387 | $99,000 | 0.02% | |
| 2. | 96 | $25,000 | 0% |
News See All
Pharmacyclics (PCYC), DIRECTV (DTV), Actavis (ACT): Farallon Capital Betting On Merger Arb Plays
Farallon Capital Management, the fund founded by Thomas Steyer in 1986, has filed its 13F for the reporting period of March 31, disclosing an equity portfolio valued at $6.85 billion as of the end of...
Pharmacyclics, Inc. (PCYC), Horizon Pharma PLC (HZNP), Auspex Pharmaceuticals Inc (ASPX): Hedge Fund's Cashing In On Highest Q1 Gainers
The first quarter is up, and our data analytics show that the top three gainers for the quarter were all biotechnology or biopharmaceutical companies and included Pharmacyclics, Inc.
Baker Bros. Advisors Hits the Jackpot with Pharmacyclics Inc (PCYC) Sale; Incyte Corporation (INCY) Among Fund’s Other Top Picks
Julian Baker and Felix Baker's Baker Bros. Advisors’ top pick from the end of 2014 has paid off for the fund in a big way in 2015.
Baker Bros. Advisors Reduces Exposure to MEI Pharma Inc (MEIP) to 3.4%
Julian and Felix Baker's Baker Bros. Advisors has decreased its stake in MEI Pharma Inc (NASDAQ:MEIP) to 746,521 shares, from 1,130,317 shares revealed as held earlier.
Baker Bros. Strengthens Position in Seattle Genetics, Inc. (SGEN)
Julian Baker and Felix Baker have increased their exposure to Seattle Genetics, Inc. (NASDAQ:SGEN) even higher.
Hedge Fund News: Bill Miller, Richard Perry & Alphonse Fletcher
Legg Mason’s Bill Miller is struggling to find the ‘extraordinary’ value in the US he did last year, and said equity markets could rise even higher in 2014.
Sanofi SA (ADR) (SNY), Roche Holding Ltd. (ADR) (RHHBY), GlaxoSmithKline plc (ADR) (GSK): Is the Tide About to Turn in the Fight Against Chronic Lymphocytic Leukemia?
There is perhaps nothing scarier than a cancer diagnosis.
Alexion Pharmaceuticals, Inc. (ALXN), Pharmacyclics, Inc. (PCYC), Aegerion Pharmaceuticals, Inc. (AEGR), Raptor Pharmaceutical Corp. (RPTP): Have These Four Biotechs Peaked?
Biotechnology stocks often trade with excessive valuations, until one day, large losses occur.
Santarus, Inc. (SNTS), Pharmacyclics, Inc. (PCYC), Ariad Pharmaceuticals, Inc. (ARIA): Should You Jump on This Biotech After Profit-Taking?
After a truly remarkable 20-month 650% gain, shares of Santarus, Inc. (NASDAQ:SNTS) have fallen by more than 20% since its all-time high in early August.
Hedge Fund Resource Center